VR Logo

Novavax Inc. (NVAX) download report


Healthcare | Biotechnology & Pharma Research

Novavax Inc. (NVAX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.

IPO Date: 05-Dec-1995

Pres, CEO & Director: Mr. Stanley Charles Erck

Exec. VP, CFO & Treasurer: Mr. James Patrick Kelly C.F.A.

Listing: NASDAQ: NVAX

Country: United States

Headquarters: Gaithersburg, MD

Website: https://www.novavax.com

Key Facts

Market cap: $4,709.17 Mln

Revenue (TTM): $1,303.73 Mln

Earnings (TTM): $-1,317.62 Mln

Cash: $1,570.95 Mln

Total Debt: $440.50 Mln

Insider's Holding: 0.46%

Liquidity: Low

52 Week range: $34.88 - 277.80

Shares outstanding: 78,134,600

10 Years Aggregate:

  • CFO: $-691.90 Mln
  • EBITDA: $-3,086.42 Mln
  • Net Profit: $-3,263.56 Mln

Stock Performance

Time Period Novavax (NVAX) S&P BSE Sensex S&P Small-Cap 600
YTD-59.051.03-11.02
1 month-19.908.638.78
3 months2.247.333.18
1 Year-69.158.43-8.04
3 Years133.1917.0610.57
5 Years24.9912.777.85
10 Years3.3312.8310.71
As on 08-Aug-2022
Year Novavax (NVAX) S&P Small-Cap 600 S&P BSE Sensex
202128.3025.2721.99
20202,701.769.5715.75
2019-89.1820.8614.38
201848.07-9.705.87
2017-1.5911.7327.91
2016-84.9824.741.95
201541.48-3.36-5.03